vs
博士伦（BLCO）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是越洋钻探的1.3倍（$1.4B vs $1.0B），越洋钻探净利率更高（2.4% vs -4.1%，领先6.5%），博士伦同比增速更快（9.8% vs 9.6%），越洋钻探自由现金流更多（$321.0M vs $60.0M），过去两年越洋钻探的营收复合增速更高（16.9% vs 13.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
BLCO vs RIG — 直观对比
营收规模更大
BLCO
是对方的1.3倍
$1.0B
营收增速更快
BLCO
高出0.2%
9.6%
净利率更高
RIG
高出6.5%
-4.1%
自由现金流更多
RIG
多$261.0M
$60.0M
两年增速更快
RIG
近两年复合增速
13.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.0B |
| 净利润 | $-58.0M | $25.0M |
| 毛利率 | — | 42.0% |
| 营业利润率 | 8.0% | 23.0% |
| 净利率 | -4.1% | 2.4% |
| 营收同比 | 9.8% | 9.6% |
| 净利润同比 | -1833.3% | 257.1% |
| 每股收益（稀释后） | $-0.16 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCORIG
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.3B | $988.0M | ||
| Q1 25 | $1.1B | $906.0M | ||
| Q4 24 | $1.3B | $952.0M | ||
| Q3 24 | $1.2B | $948.0M | ||
| Q2 24 | $1.2B | $861.0M | ||
| Q1 24 | $1.1B | $763.0M |
净利润BLCORIG
| Q4 25 | $-58.0M | $25.0M | ||
| Q3 25 | $-28.0M | $-1.9B | ||
| Q2 25 | $-62.0M | $-938.0M | ||
| Q1 25 | $-212.0M | $-79.0M | ||
| Q4 24 | $-3.0M | $7.0M | ||
| Q3 24 | $4.0M | $-494.0M | ||
| Q2 24 | $-151.0M | $-123.0M | ||
| Q1 24 | $-167.0M | $98.0M |
毛利率BLCORIG
| Q4 25 | — | 42.0% | ||
| Q3 25 | — | 43.2% | ||
| Q2 25 | — | 39.4% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 39.2% | ||
| Q3 24 | — | 40.6% | ||
| Q2 24 | — | 38.0% | ||
| Q1 24 | — | 31.5% |
营业利润率BLCORIG
| Q4 25 | 8.0% | 23.0% | ||
| Q3 25 | 7.4% | -163.1% | ||
| Q2 25 | -0.9% | -97.6% | ||
| Q1 25 | -7.3% | 7.1% | ||
| Q4 24 | 6.8% | 13.7% | ||
| Q3 24 | 3.6% | -51.2% | ||
| Q2 24 | 2.1% | -6.9% | ||
| Q1 24 | 0.5% | -0.4% |
净利率BLCORIG
| Q4 25 | -4.1% | 2.4% | ||
| Q3 25 | -2.2% | -187.1% | ||
| Q2 25 | -4.9% | -94.9% | ||
| Q1 25 | -18.6% | -8.7% | ||
| Q4 24 | -0.2% | 0.7% | ||
| Q3 24 | 0.3% | -52.1% | ||
| Q2 24 | -12.4% | -14.3% | ||
| Q1 24 | -15.2% | 12.8% |
每股收益（稀释后）BLCORIG
| Q4 25 | $-0.16 | $0.13 | ||
| Q3 25 | $-0.08 | $-2.00 | ||
| Q2 25 | $-0.18 | $-1.06 | ||
| Q1 25 | $-0.60 | $-0.11 | ||
| Q4 24 | $-0.00 | $-0.14 | ||
| Q3 24 | $0.01 | $-0.58 | ||
| Q2 24 | $-0.43 | $-0.15 | ||
| Q1 24 | $-0.48 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $620.0M |
| 总债务越低越好 | $5.0B | $5.2B |
| 股东权益账面价值 | $6.4B | $8.1B |
| 总资产 | $14.0B | $15.6B |
| 负债/权益比越低杠杆越低 | 0.78× | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资BLCORIG
| Q4 25 | $383.0M | $620.0M | ||
| Q3 25 | $310.0M | $833.0M | ||
| Q2 25 | $266.0M | $377.0M | ||
| Q1 25 | $202.0M | $263.0M | ||
| Q4 24 | $305.0M | $560.0M | ||
| Q3 24 | $329.0M | $435.0M | ||
| Q2 24 | $285.0M | $475.0M | ||
| Q1 24 | $315.0M | $446.0M |
总债务BLCORIG
| Q4 25 | $5.0B | $5.2B | ||
| Q3 25 | $5.0B | $4.8B | ||
| Q2 25 | $5.0B | $5.9B | ||
| Q1 25 | $4.8B | $5.9B | ||
| Q4 24 | $4.8B | $6.2B | ||
| Q3 24 | $4.6B | $6.5B | ||
| Q2 24 | $4.6B | $6.8B | ||
| Q1 24 | $4.6B | $6.8B |
股东权益BLCORIG
| Q4 25 | $6.4B | $8.1B | ||
| Q3 25 | $6.4B | $8.1B | ||
| Q2 25 | $6.4B | $9.4B | ||
| Q1 25 | $6.4B | $10.2B | ||
| Q4 24 | $6.5B | $10.3B | ||
| Q3 24 | $6.6B | $10.2B | ||
| Q2 24 | $6.5B | $10.7B | ||
| Q1 24 | $6.7B | $10.5B |
总资产BLCORIG
| Q4 25 | $14.0B | $15.6B | ||
| Q3 25 | $13.8B | $16.2B | ||
| Q2 25 | $13.8B | $17.8B | ||
| Q1 25 | $13.4B | $19.0B | ||
| Q4 24 | $13.5B | $19.4B | ||
| Q3 24 | $13.5B | $19.5B | ||
| Q2 24 | $13.3B | $20.3B | ||
| Q1 24 | $13.3B | $19.9B |
负债/权益比BLCORIG
| Q4 25 | 0.78× | 0.64× | ||
| Q3 25 | 0.77× | 0.60× | ||
| Q2 25 | 0.77× | 0.63× | ||
| Q1 25 | 0.76× | 0.58× | ||
| Q4 24 | 0.74× | 0.60× | ||
| Q3 24 | 0.70× | 0.64× | ||
| Q2 24 | 0.71× | 0.63× | ||
| Q1 24 | 0.69× | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $321.0M |
| 自由现金流率自由现金流/营收 | 4.3% | 30.8% |
| 资本支出强度资本支出/营收 | 5.4% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 13.96× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $626.0M |
8季度趋势，按日历期对齐
经营现金流BLCORIG
| Q4 25 | $136.0M | $349.0M | ||
| Q3 25 | $137.0M | $246.0M | ||
| Q2 25 | $35.0M | $128.0M | ||
| Q1 25 | $-25.0M | $26.0M | ||
| Q4 24 | $22.0M | $206.0M | ||
| Q3 24 | $154.0M | $194.0M | ||
| Q2 24 | $15.0M | $133.0M | ||
| Q1 24 | $41.0M | $-86.0M |
自由现金流BLCORIG
| Q4 25 | $60.0M | $321.0M | ||
| Q3 25 | $63.0M | $235.0M | ||
| Q2 25 | $-54.0M | $104.0M | ||
| Q1 25 | $-135.0M | $-34.0M | ||
| Q4 24 | $-70.0M | $177.0M | ||
| Q3 24 | $94.0M | $136.0M | ||
| Q2 24 | $-57.0M | $49.0M | ||
| Q1 24 | $-26.0M | $-169.0M |
自由现金流率BLCORIG
| Q4 25 | 4.3% | 30.8% | ||
| Q3 25 | 4.9% | 22.9% | ||
| Q2 25 | -4.2% | 10.5% | ||
| Q1 25 | -11.9% | -3.8% | ||
| Q4 24 | -5.5% | 18.6% | ||
| Q3 24 | 7.9% | 14.3% | ||
| Q2 24 | -4.7% | 5.7% | ||
| Q1 24 | -2.4% | -22.1% |
资本支出强度BLCORIG
| Q4 25 | 5.4% | 2.7% | ||
| Q3 25 | 5.8% | 1.1% | ||
| Q2 25 | 7.0% | 2.4% | ||
| Q1 25 | 9.7% | 6.6% | ||
| Q4 24 | 7.2% | 3.0% | ||
| Q3 24 | 5.0% | 6.1% | ||
| Q2 24 | 5.9% | 9.8% | ||
| Q1 24 | 6.1% | 10.9% |
现金转化率BLCORIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
